(PDF) OL3, a Novel Low-Absorbed TGR5 Agonist With Reduced

OL3, a Novel Low-Absorbed TGR5 Agonist With Reduced Side Effects, Lowered Blood Glucose via Dual Actions on TGR5 Activation and DPP-4 Inhibition

Acta Pharmacologica Sinica - United Kingdom

doi 10.1038/aps.2016.27

Full Text

Abstract

Available in full text

Categories

Date

June 6, 2016

Authors

Publisher

Springer Science and Business Media LLC

Related search

Effects of Chemical Modification of Ursodeoxycholic Acid on TGR5 Activation

Biological and Pharmaceutical Bulletin

Pharmaceutical Science

English

Activation of TGR5 Partially Alleviates High Glucose-Induced Cardiomyocyte Injury by Inhibition of Inflammatory Responses and Oxidative Stress

Oxidative Medicine and Cellular Longevity

English

TGR5 Activation Promotes Stimulus-Secretion Coupling of Pancreatic Beta-Cells via a PKA-Dependent Pathway

Internal Medicine

English

Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet Α Cells to Promote Glucose Homeostasis

Journal of Biological Chemistry

Molecular Biology

English

TGR5 Activation Ameliorates Hyperglycemia-Induced Cardiac Hypertrophy in H9c2 Cells

Scientific Reports

Multidisciplinary

English

Ginsenoside Rg1, a Novel Glucocorticoid Receptor Agonist of Plant Origin, Maintains Glucocorticoid Efficacy With Reduced Side Effects

Journal of Immunology

English

DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?

Internal Medicine

English

Erratum To: DPP-4 Inhibitors in Diabetic Complications: Role of DPP-4 Beyond Glucose Control

Archives of Pharmacal Research

Organic Chemistry

Molecular Medicine

English

Combination of PPAR-α Agonist and DPP-4 Inhibitor: A Novel Therapeutic Approach in the Management of Diabetic Nephropathy

Journal of Diabetes & Metabolism

English